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Recent increases in pathology costs per scheme member are a concern to medical schemes and pathologists alike. To better understand the 
observed increasing costs, the National Pathology Group commissioned Prognosys to analyse the trends affecting these increases. We found 
that these increases are driven by inflation, increases in utilisation, and redistribution of the burden of cost. The identification of utilisation 
as a cost driver for pathology services is noteworthy as almost all pathology services are by referral from another doctor.
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Above-inflation increases in pathology costs per 
scheme member are a concern to medical schemes. 
To better understand the observed increasing costs, 
the National Pathology Group (NPG) commissioned 
Prognosys (an independent actuarial company) to 
analyse the trends affecting the increases. Prognosys used only 
publicly available information for this research. These data were 
compiled from the Council for Medical Schemes’ latest annual reports 
and annual statutory returns as well as supplementary data from 
Statistics South Africa (SA). This article has been prepared using this 
research, which was completed in May 2013.
While pathology costs are a small proportion of the total expenditure 
on private healthcare, expenditure on pathology has increased in the 
5-year period from 2006 to 2011. 
Pathology costs per beneficiary increased by 72% in nominal terms 
(i.e. before adjusting for inflation) from 2006 to 2011. In real terms (i.e. 
after adjustment for inflation) pathology expenditure has experienced 
an increase of 23% in this period. This is equivalent to an average 
annual increase of 4.21% above inflation. In contrast, overall average 
benefits paid per beneficiary have increased by 53% in nominal terms 
and 8.94% in real terms. This equates to an average annual increase of 
1.84% above inflation.
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The most important findings were:
• That the increase in pathology costs is 
driven by an utilisation increase of 18%
• When correcting for increase in 
utilisation, pathology costs per utilisation 
(CPU) have increased by only 3.78% in 
real terms. This is below the increase in 
overall benefits of 8.94% in real terms.
The identification of utilisation as a cost 
driver for pathology services is noteworthy 
as almost all pathology services are by 
referral from another doctor. 
As a result of the decrease in the burden of 
pathology costs borne by members, the real 
increase in charges of 13% by pathologists 
translated to a real increase of 23% for medical 
schemes. The most likely explanation for this 
movement of the cost burden is the payment 
of costs related to Prescribed Minimum 
Benefits (PMB) conditions, which now have 
to be paid in full by schemes. 
Further work needs to be done to understand 
factors contributing to the increased utilisation. 
Factors that could be playing a role are:
• Disease management initiatives
• Improved disease screening
• Defensive medicine against the backdrop 
of increased medical malpractice litigation.
However, the largest health quality survey in 
the SA private sector reports that members 
with HIV on antiretroviral medication on 
average only have a CD4 or viral load test 
every second year and that members with 
diabetes mellitus only have an HbA1C test 
every second year. This suggests that there 
has not been an improvement in disease risk 
management initiatives across the industry. 
Trends in scheme benefit 
expenditure
Medical schemes and their members have 
seen benefit expenditure rise steadily at a 
rate above inflation. Fig. 1 presents the claim 
costs per average beneficiary per annum 
for each year from 2006 to 2011. The graph 
highlights the direct impact of pathology 
cost increases over the period. 
Fig. 1 reveals a trend of increasing benefit 
costs for medical schemes. This increase is 
equivalent to an average increase of 8.94% 
(1.84% above inflation) per annum from 2006 
to 2011. Pathology costs have also increased in 
this period with their share of total claim costs 
increasing, from 4.2% in 2006 to 4.7% in 2011. 
Pathology utilisation
Pathology utilisation has increased cumu-
latively by 18% since 2006. This increase 
must be seen in light of the large increases in 
pathology utilisation against a background 
of relative stability in pathology CPU since 
2006. 
From Fig. 2 it is clear that real pathology 
CPU have fluctuated at around 4% above 
2006 levels for the last four years, while 
hospital CPU and medical specialists’ CPU 
have been increasing.
It must be stressed that this measure does 
not take into account possible changes in the 
age of members, the burden of disease, the 
length of stay in hospitals, or the complexity 
of cases. Furthermore, the utilisation measure 
does not reflect the number of pathology tests 
run, but the number of pathology claims. 
These factors could affect the comparability 
of the CPU at different points in time.
This increase in pathology costs, whether 
borne by members or schemes, needs to be 
better understood to avoid the implementation 
of counter-productive interventions. Ideally, 
this cost should be assessed relative to 
consequent changes in health outcomes. 
Given the limitations of available public 
data, this report focused on details regarding 
benefit expenditure trends, utilisation, and 
CPU for pathology (and other categories of 
expenditure). 
More research must be done to understand 
the factors driving the observed increased in 
utilisation. This research should include an 
analysis of which pathology tests are being 
performed more often, as well as the reasons 
for these tests being requested. 
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Fig. 1. Claims paid per average beneficiary per annum (pabpa).
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Fig. 2. Cumulative growth in real benefits per utilisation per annum since 2006.
